The Global Cord Blood and Tissue Banking Services Market is composed of revenue produced by companies that are engaged with the collection, processing, storage, and release of umbilical cord blood and tissue products. The global cord blood industry came into existence in the early 1990’s with the formation of a handful of cord blood banks within the United States. Shortly thereafter, these companies began being established in other regions as well. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Global Cord Blood Banking Industry Report – Market Size, Segments, and Trends
BioInformant, the first and only market research firm to specialize in the stem cell industry, announces the release of its “Global Cord Blood & Tissue Banking Industry Report – Market Size, Segmentation, & Forecasts, 2024.” This market report reveals key forces affecting the industry, presenting trend rate data for cord blood and tissue clinical trials, patents, grants, and scientific publications. It reveals public and private storage counts for cord blood and tissue on a global basis, as well as market size metrics for the public and private sectors, accompanied by future forecasts.
AABB Releases New Resources and Initiatives For its Certified Advanced Biotherapies Professional (CABP) Program
May 1, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce several new offerings as part of its Certified Advanced Biotherapies Professional (CABP) credentialing program. These updates, released to make the CABP program more accessible to biotherapies professionals and organizations, include: [Read more…]
NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development
First of Its Kind Clinical-Grade Leukopak Now Facilitates Easier Regulatory Filing with Access to a DMF and Identification of Additional Characteristics Required to Qualify Cord Blood Units as Starting Material for Manufacture of Cell and Gene Therapies
MINNEAPOLIS– NMDP BioTherapies℠ formerly Be The Match BioTherapies, a leader in cell and gene therapy development support, unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings. The strategic enhancements to its suite are designed to address the evolving needs of the allogeneic cell therapy industry, emphasizing optimized delivery times, customizable options, and expanded capabilities. [Read more…]
Cryo-Cell to Spin-off Celle Corp., Its Subsidiary Holding Assets Not Directly Associated with Recurring Revenue from Biopreservation
Celle Corp. holds certain assets of Cryo-Cell not directly associated with its recurring revenue derived from privately banked cord blood specimens.
OLDSMAR, Fla.–Cryo-Cell International, Inc. (NYSE American LLC: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or debt financings and/or the possible sale or merger of the company. There is no assurance that such a transaction will take place. [Read more…]
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 62
- Next Page »